Radioligand Therapy
Radioligand therapy (RLT) leverages the precision of molecular targeting to bring radioactive particles, also known as radionuclides or radioisotopes, directly to cancer cells, even when they’ve spread throughout the body. Radioligands are made up of a ligand, which recognizes and binds to the target molecule on cancer cells or within the tumor microenvironment, and a radionuclide, which is held by a chelator and linked to the ligand.
Explore our radioligand therapy clinical trial
For information on trial enrollment, locations, and more, call
1-800-545-5979.
or visit www.clinicaltrials.gov for more information on this trial
This website was commissioned by Lilly Medical and is indicated to be used by HCPs for medical, scientific, and educational purposes.
The safety and efficacy of the agents for uses under investigation have not been established. Pipeline molecules may not receive regulatory approval and become commercially available for the uses being investigated. The information provided about new molecules being studied is for scientific information exchange purposes only with no commercial intent.
